稿を終えるにあたり、始終多大なる御指導、御鞭撻および御校閲を賜りました 熊本大学大学 院生命科学研究部 香月 博志 教授に深甚なる感謝の意を表します。
本論文の審査にあたり、有益なる御助言と御校閲を賜りました 熊本大学大学院 生命科学研 究部 杉本 幸彦 教授、石塚 洋一 准教授ならびに伊藤 慎悟 准教授に厚く御礼申し上げ ます。
本研究に際し、多大なる御指導、御鞭撻を賜りました 京都大学 赤池 昭紀 名誉教授、武 田薬品工業株式会社 木村 温英 リサーチマネージャーならびに武田薬品工業株式会社 鈴木 基久 主席研究員に深謝致します。
引用文献
1. Imbimbo BP, Lombard J, Pomara N. Pathophysiology of Alzheimers disease. Neuroimaging Clin N Am. 15: 727-53, ix (2005)
2. Kalia LV, Lang AE. Parkinsons disease. Lancet. 386: 896-912 (2015)
3. Esposito E, Cuzzocrea S. New therapeutic strategy for Parkinsons and Alzheimers disease. Curr Med Chem. 17: 2764-74 (2010)
4. Reeve A, Simcox E, Turnbull D. Ageing and Parkinsons disease: why is advancing age the biggest risk factor? Ageing Res Rev. 14: 19-30 (2014)
5. Moustafa AA, Chakravarthy S, Phillips JR, Gupta A, Keri S, Polner B, et al. Motor symptoms in Parkinsons disease: A unified framework. Neurosci Biobehav Rev. 68: 727-40 (2016)
6. Gerhard A, Pavese N, Hotton G, Turkheimer F, Es M, Hammers A, et al. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinsons disease. Neurobiol Dis.
21: 404-12 (2006)
7. Tansey MG, McCoy MK, Frank-Cannon TC. Neuroinflammatory mechanisms in Parkinsons disease: potential environmental triggers, pathways, and targets for early therapeutic intervention.
Exp Neurol. 208: 1-25 (2007)
8. Young J, Mendoza M. Parkinsons disease: A treatment guide. J Fam Pract. 67:276;279;284;286 (2018)
9. Maden M. Retinoic acid in the development, regeneration and maintenance of the nervous system.
Nat Rev Neurosci. 8: 755-65 (2007)
10. Mingaud F, Mormede C, Etchamendy N, Mons N, Niedergang B, Wietrzych M, et al. Retinoid hyposignaling contributes to aging-related decline in hippocampal function in short-term/working memory organization and long-term declarative memory encoding in mice. J Neurosci. 28: 279-91 (2008)
11. Dheen ST, Jun Y, Yan Z, Tay SS, Ling EA. Retinoic acid inhibits expression of TNF-alpha and iNOS in activated rat microglia. Glia. 50: 21-31 (2005)
12. Xu J, Drew PD. 9-Cis-retinoic acid suppresses inflammatory responses of microglia and astrocytes. J Neuroimmunol. 171: 135-44 (2006)
13. Alzheimers A. 2013 Alzheimers disease facts and figures. Alzheimers Dement. 9: 208-45 (2013) 14. Singh M, Kaur M, Kukreja H, Chugh R, Silakari O, Singh D. Acetylcholinesterase inhibitors as
Alzheimer therapy: from nerve toxins to neuroprotection. Eur J Med Chem. 70: 165-88 (2013) 15. Kulshreshtha A, Piplani P. Current pharmacotherapy and putative disease-modifying therapy for
Alzheimers disease. Neurol Sci. 37: 1403-35 (2016)
16. Fisher A, Heldman E, Gurwitz D, Haring R, Karton Y, Meshulam H, et al. M1 agonists for the treatment of Alzheimers disease. Novel properties and clinical update. Ann N Y Acad Sci. 777:
189-96 (1996)
17. Bodick NC, Offen WW, Shannon HE, Satterwhite J, Lucas R, van Lier R, et al. The selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer disease. Alzheimer Dis Assoc Disord. 11 Suppl 4: S16-22 (1997)
18. Iga Y, Arisawa H, Ogane N, Saito Y, Tomizuka T, Nakagawa-Yagi Y, et al.
(+/-)-cis-2-methylspiro[1,3-oxathiolane-5,3 -quinuclidine] hydrochloride, hemihydrate (SNI-2011, cevimeline hydrochloride) induces saliva and tear secretions in rats and mice: the role of muscarinic acetylcholine receptors. Jpn J Pharmacol. 78: 373-80 (1998)
19. Sako Y, Kurimoto E, Mandai T, Suzuki A, Tanaka M, Suzuki M, et al. TAK-071, a novel M1 positive allosteric modulator with low cooperativity, improves cognitive function in rodents with few cholinergic side effects. Neuropsychopharmacology. 44: 950-60 (2019)
20. McCaffery P, Drager UC. High levels of a retinoic acid-generating dehydrogenase in the meso-telencephalic dopamine system. Proc Natl Acad Sci U S A. 91: 7772-6 (1994)
21. Ruberte E, Friederich V, Chambon P, Morriss-Kay G. Retinoic acid receptors and cellular retinoid binding proteins. III. Their differential transcript distribution during mouse nervous system development. Development. 118: 267-82 (1993)
22. Galter D, Buervenich S, Carmine A, Anvret M, Olson L. ALDH1 mRNA: presence in human dopamine neurons and decreases in substantia nigra in Parkinsons disease and in the ventral tegmental area in schizophrenia. Neurobiol Dis. 14: 637-47 (2003)
23. McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinsons and Alzheimers disease brains . Neurology. 38: 1285-91 (1988) 24. Whitton PS. Inflammation as a causative factor in the aetiology of Parkinsons disease. Br J
Pharmacol. 150: 963-76 (2007)
25. Iravani MM, Kashefi K, Mander P, Rose S, Jenner P. Involvement of inducible nitric oxide synthase in inflammation-induced dopaminergic neurodegeneration. Neuroscience. 110: 49-58 (2002)
26. Shibata H, Katsuki H, Nishiwaki M, Kume T, Kaneko S, Akaike A. Lipopolysaccharide-induced dopaminergic cell death in rat midbrain slice cultures: role of inducible nitric oxide synthase and protection by indomethacin. J Neurochem. 86: 1201-12 (2003)
27. Katsuki H, Okawara M, Shibata H, Kume T, Akaike A. Nitric oxide-producing microglia mediate thrombin-induced degeneration of dopaminergic neurons in rat midbrain slice culture. J Neurochem.
97: 1232-42 (2006)
28. Kagechika H, Kawachi E, Hashimoto Y, Himi T, Shudo K. Retinobenzoic acids. 1. Structure-activity relationships of aromatic amides with retinoidal activity. J Med Chem. 31: 2182-92 (1988)
29. Yamakawa T, Kagechika H, Kawachi E, Hashimoto Y, Shudo K. Retinobenzoic acids. 5. Retinoidal activities of compounds having a trimethylsilyl or trimethylgermyl group(s) in human promyelocytic leukemia cells HL-60. J Med Chem. 33: 1430-7 (1990)
30. Umemiya H, Kagechika H, Fukasawa H, Kawachi E, Ebisawa M, Hashimoto Y, et al. Action mechanism of retinoid-synergistic dibenzodiazepines. Biochem Biophys Res Commun. 233: 121-5 (1997)
31. Arai H, Furuya T, Yasuda T, Miura M, Mizuno Y, Mochizuki H. Neurotoxic effects of lipopolysaccharide on nigral dopaminergic neurons are mediated by microglial activation, interleukin-1beta, and expression of caspase-11 in mice. J Biol Chem. 279: 51647-53 (2004)
32. Kurauchi Y, Hisatsune A, Isohama Y, Katsuki H. Nitric oxide-cyclic GMP signaling pathway limits inflammatory degeneration of midbrain dopaminergic neurons: cell type-specific regulation of heme oxygenase-1 expression. Neuroscience. 158: 856-66 (2009)
33. Sun SY, Yue P, Dawson MI, Shroot B, Michel S, Lamph WW, et al. Differential effects of synthetic nuclear retinoid receptor-selective retinoids on the growth of human non-small cell lung carcinoma cells. Cancer Res. 57: 4931-9 (1997)
34. Umemiya H, Fukasawa H, Ebisawa M, Eyrolles L, Kawachi E, Eisenmann G, et al. Regulation of retinoidal actions by diazepinylbenzoic acids. Retinoid synergists which activate the RXR-RAR heterodimers. J Med Chem. 40: 4222-34 (1997)
35. Mey J. New therapeutic target for CNS injury? The role of retinoic acid signaling after nerve lesions.
J Neurobiol. 66: 757-79 (2006)
36. Bespalov MM, Saarma M. GDNF family receptor complexes are emerging drug targets. Trends Pharmacol Sci. 28: 68-74 (2007)
37. Hu Y, Russek SJ. BDNF and the diseased nervous system: a delicate balance between adaptive and pathological processes of gene regulation. J Neurochem. 105: 1-17 (2008)
38. Masia S, Alvarez S, de Lera AR, Barettino D. Rapid, nongenomic actions of retinoic acid on phosphatidylinositol-3-kinase signaling pathway mediated by the retinoic acid receptor. Mol Endocrinol. 21: 2391-402 (2007)
39. Borta A, Hoglinger GU. Dopamine and adult neurogenesis. J Neurochem. 100: 587-95 (2007)
40. Al Tanoury Z, Piskunov A, Rochette-Egly C. Vitamin A and retinoid signaling: genomic and nongenomic effects. J Lipid Res. 54: 1761-75 (2013)
41. Chen N, Napoli JL. All-trans-retinoic acid stimulates translation and induces spine formation in hippocampal neurons through a membrane-associated RARalpha. FASEB J. 22: 236-45 (2008) 42. Chen N, Onisko B, Napoli JL. The nuclear transcription factor RARalpha associates with neuronal
RNA granules and suppresses translation. J Biol Chem. 283: 20841-7 (2008)
43. Kaplan DR, Matsumoto K, Lucarelli E, Thiele CJ. Induction of TrkB by retinoic acid mediates biologic responsiveness to BDNF and differentiation of human neuroblastoma cells. Eukaryotic Signal Transduction Group. Neuron. 11: 321-31 (1993)
44. Lucarelli E, Kaplan DR, Thiele CJ. Selective regulation of TrkA and TrkB receptors by retinoic acid and interferon-gamma in human neuroblastoma cell lines. J Biol Chem. 270: 24725-31 (1995) 45. Fumagalli F, Racagni G, Riva MA. Shedding light into the role of BDNF in the pharmacotherapy of
Parkinsons disease. Pharmacogenomics J. 6: 95-104 (2006)
46. Thang SH, Kobayashi M, Matsuoka I. Regulation of glial cell line-derived neurotrophic factor responsiveness in developing rat sympathetic neurons by retinoic acid and bone morphogenetic protein-2. J Neurosci. 20: 2917-25 (2000)
47. Canon E, Cosgaya JM, Scsucova S, Aranda A. Rapid effects of retinoic acid on CREB and ERK phosphorylation in neuronal cells. Mol Biol Cell. 15: 5583-92 (2004)
48. Greer PL, Greenberg ME. From synapse to nucleus: calcium-dependent gene transcription in the control of synapse development and function. Neuron. 59: 846-60 (2008)
49. Kurauchi Y, Hisatsune A, Isohama Y, Sawa T, Akaike T, Shudo K, et al. Midbrain dopaminergic neurons utilize nitric oxide/cyclic GMP signaling to recruit ERK that links retinoic acid receptor stimulation to up-regulation of BDNF. J Neurochem. 116: 323-33 (2011)
50. Segal RA. Selectivity in neurotrophin signaling: theme and variations. Annu Rev Neurosci. 26:
299-330 (2003)
51. Levey AI. Muscarinic acetylcholine receptor expression in memory circuits: implications for treatment of Alzheimer disease. Proc Natl Acad Sci U S A. 93: 13541-6 (1996)
52. Tsang SW, Lai MK, Kirvell S, Francis PT, Esiri MM, Hope T, et al. Impaired coupling of muscarinic M1 receptors to G-proteins in the neocortex is associated with severity of dementia in Alzheimers disease. Neurobiol Aging. 27: 1216-23 (2006)
53. Bartolomeo AC, Morris H, Buccafusco JJ, Kille N, Rosenzweig-Lipson S, Husbands MG, et al. The preclinical pharmacological profile of WAY-132983, a potent M1 preferring agonist. J Pharmacol Exp Ther. 292: 584-96 (2000)
54. Cui Y, Wang D, Si W, Lv W, Niu Y, Lei X, et al. Enhancement of memory function in aged mice by a novel derivative of xanomeline. Cell Res. 18: 1151-3 (2008)
55. Ma L, Seager MA, Wittmann M, Jacobson M, Bickel D, Burno M, et al. Selective activation of the M1 muscarinic acetylcholine receptor achieved by allosteric potentiation. Proc Natl Acad Sci U S A.
106: 15950-5 (2009)
56. Shirey JK, Brady AE, Jones PJ, Davis AA, Bridges TM, Kennedy JP, et al. A selective allosteric potentiator of the M1 muscarinic acetylcholine receptor increases activity of medial prefrontal cortical neurons and restores impairments in reversal learning. J Neurosci. 29: 14271-86 (2009) 57. Si W, Zhang X, Niu Y, Yu H, Lei X, Chen H, et al. A novel derivative of xanomeline improves fear
cognition in aged mice. Neurosci Lett. 473: 115-9 (2010)
58. Medeiros R, Kitazawa M, Caccamo A, Baglietto-Vargas D, Estrada-Hernandez T, Cribbs DH, et al.
Loss of muscarinic M1 receptor exacerbates Alzheimers disease -like pathology and cognitive decline. Am J Pathol. 179: 980-91 (2011)
59. Davie BJ, Christopoulos A, Scammells PJ. Development of M1 mAChR allosteric and bitopic ligands: prospective therapeutics for the treatment of cognitive deficits. ACS Chem Neurosci. 4:
1026-48 (2013)
60. Uslaner JM, Eddins D, Puri V, Cannon CE, Sutcliffe J, Chew CS, et al. The muscarinic M1 receptor positive allosteric modulator PQCA improves cognitive measures in rat, cynomolgus macaque, and rhesus macaque. Psychopharmacology (Berl). 225: 21-30 (2013)
61. Jiang S, Li Y, Zhang C, Zhao Y, Bu G, Xu H, et al. M1 muscarinic acetylcholine receptor in Alzheimers disease. Neurosci Bull. 30: 295-307 (2014)
62. Vardigan JD, Cannon CE, Puri V, Dancho M, Koser A, Wittmann M, et al. Improved cognition without adverse effects: novel M1 muscarinic potentiator compares favorably to donepezil and xanomeline in rhesus monkey. Psychopharmacology (Berl). 232: 1859-66 (2015)
63. Conn PJ, Christopoulos A, Lindsley CW. Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat Rev Drug Discov. 8: 41-54 (2009)
64. Canals M, Lane JR, Wen A, Scammells PJ, Sexton PM, Christopoulos A. A Monod-Wyman-Changeux mechanism can explain G protein-coupled receptor (GPCR) allosteric modulation. J Biol Chem. 287: 650-9 (2012)
65. Abdul-Ridha A, Lane JR, Sexton PM, Canals M, Christopoulos A. Allosteric modulation of a chemogenetically modified G protein-coupled receptor. Mol Pharmacol. 83: 521-30 (2013)
66. Mistry SN, Valant C, Sexton PM, Capuano B, Christopoulos A, Scammells PJ. Synthesis and pharmacological profiling of analogues of benzyl quinolone carboxylic acid (BQCA) as allosteric modulators of the M1 muscarinic receptor. J Med Chem. 56: 5151-72 (2013)
67. Leach K, Sexton PM, Christopoulos A. Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology. Trends Pharmacol Sci. 28: 382-9 (2007)
68. Lazareno S, Birdsall NJ. Detection, quantitation, and verification of allosteric interactions of agents with labeled and unlabeled ligands at G protein-coupled receptors: interactions of strychnine and acetylcholine at muscarinic receptors. Mol Pharmacol. 48: 362-78 (1995)
69. Hughes RN. The value of spontaneous alternation behavior (SAB) as a test of retention in pharmacological investigations of memory. Neurosci Biobehav Rev. 28: 497-505 (2004)
70. Caulfield MP. Muscarinic receptors--characterization, coupling and function. Pharmacol Ther. 58:
319-79 (1993)
71. Nathan PJ, Watson J, Lund J, Davies CH, Peters G, Dodds CM, et al. The potent M1 receptor allosteric agonist GSK1034702 improves episodic memory in humans in the nicotine abstinence model of cognitive dysfunction. Int J Neuropsychopharmacol. 16: 721-31 (2013)
72. Fosbraey P, Johnson ES. Modulation by acetylcholine of the electrically-evoked release of [3H]-acetylcholine from the ileum of the guinea-pig. Br J Pharmacol. 69: 145-9 (1980)
73. Hayashi E, Maeda T, Shinozuka K. Adenosine and dipyridamole: actions and interactions on the contractile response of guinea-pig ileum to high frequency electrical field stimulation. Br J Pharmacol. 84: 765-71 (1985)
74. Takeuchi T, Fujinami K, Goto H, Fujita A, Taketo MM, Manabe T, et al. Roles of M2 and M4 muscarinic receptors in regulating acetylcholine release from myenteric neurons of mouse ileum. J Neurophysiol. 93: 2841-8 (2005)
75. Eglen RM, Hegde SS, Watson N. Muscarinic receptor subtypes and smooth muscle function.
Pharmacol Rev. 48: 531-65 (1996)
76. Matsui M, Motomura D, Fujikawa T, Jiang J, Takahashi S, Manabe T, et al.
77. Mice lacking M2 and M3 muscarinic acetylcholine receptors are devoid of cholinergic smooth muscle contractions but still viable. J Neurosci. 22: 10627-32 (2002)
78. Unno T, Matsuyama H, Izumi Y, Yamada M, Wess J, Komori S. Roles of M2 and M3 muscarinic receptors in cholinergic nerve-induced contractions in mouse ileum studied with receptor knockout mice. Br J Pharmacol. 149: 1022-30 (2006)
79. Ehlert FJ, Pak KJ, Griffin MT. Muscarinic agonists and antagonists: effects on gastrointestinal function. Handb Exp Pharmacol. : 343-74 (2012)
80. Tran JA, Matsui M, Ehlert FJ. Differential coupling of muscarinic M1, M2, and M3 receptors to phosphoinositide hydrolysis in urinary bladder and longitudinal muscle of the ileum of the mouse. J Pharmacol Exp Ther. 318: 649-56 (2006)
81. Ito Y, Oyunzul L, Seki M, Fujino Oki T, Matsui M, Yamada S. Quantitative analysis of the loss of muscarinic receptors in various peripheral tissues in M1-M5 receptor single knockout mice. Br J Pharmacol. 156: 1147-53 (2009)
82. Glaza I, Szadujkis-Szadurski L, Szadujkis-Szadurski R, Gajdus M, Olkowska J. Modulating activity of M1 receptor to the reaction of ileal smooth muscle. Postepy Hig Med Dosw (Online). 65: 478-81 (2011)
83. Harrington AM, Peck CJ, Liu L, Burcher E, Hutson JM, Southwell BR. Localization of muscarinic receptors M1R, M2R and M3R in the human colon. Neurogastroenterol Motil. 22: 999-1008, e262-3 (2010)
84. Tobin G, Giglio D, Lundgren O. Muscarinic receptor subtypes in the alimentary tract. J Physiol Pharmacol. 60: 3-21 (2009)
85. John ES, Chokhavatia S. Targeting Small Bowel Receptors to Treat Constipation and Diarrhea. Curr Gastroenterol Rep. 19: 31 (2017)
86. Browning JG, Hardcastle J, Hardcastle PT, Sanford PA. The role of acetylcholine in the regulation of ion transport by rat colon mucosa. J Physiol. 272: 737-54 (1977)
87. Hirota CL, McKay DM. Cholinergic regulation of epithelial ion transport in the mammalian intestine.
Br J Pharmacol. 149: 463-79 (2006)
88. Carey HV, Tien XY, Wallace LJ, Cooke HJ. Muscarinic receptor subtypes mediating the mucosal response to neural stimulation of guinea pig ileum. Am J Physiol. 253: G323-9 (1987)
89. Bartus RT. On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp Neurol. 163: 495-529 (2000)
90. Berger H. Über das Elektrenkephalogramm des Menschen. Dritte Mitteilung. Archiv für Psychiatrie und Nervenkrankheiten. 94:16-60 (1931)
91. Berger H. Dritte Mitteilung ber das Elektrenkephalogramm des Menschen. FŰnfte Mitteilung. Arch Psychiatr Nervenkr. 98: 231-54 (1932)
92. Kowalski JW, Gawel M, Pfeffer A, Barcikowska M. The diagnostic value of EEG in Alzheimer disease: correlation with the severity of mental impairment. J Clin Neurophysiol. 18: 570-5 (2001) 93. van der Hiele K, Vein AA, Reijntjes RH, Westendorp RG, Bollen EL, van Buchem MA, et al. EEG
correlates in the spectrum of cognitive decline. Clin Neurophysiol. 118: 1931-9 (2007)
94. Balkan S, Yaras N, Mihci E, Dora B, Agar A, Yargicoglu P. Effect of donepezil on EEG spectral analysis in Alzheimers disease. Acta Neurol Belg. 103: 164-9 (2003)
95. Van Dam D, De Deyn PP. Drug discovery in dementia: the role of rodent models. Nat Rev Drug Discov. 5: 956-70 (2006)
96. Ebert U, Kirch W. Scopolamine model of dementia: electroencephalogram findings and cognitive performance. Eur J Clin Invest. 28: 944-9 (1998)
97. Kikuchi M, Wada Y, Nanbu Y, Nakajima A, Tachibana H, Takeda T, et al. EEG changes following scopolamine administration in healthy subjects. Quantitative analysis during rest and photic stimulation. Neuropsychobiology. 39: 219-26 (1999)
98. Dringenberg HC, Rubenstein ML, Solty H, Tomaszek S, Bruce A. Electroencephalographic activation by tacrine, deprenyl, and quipazine: cholinergic vs. non-cholinergic contributions. Eur J Pharmacol. 447: 43-50 (2002)
99. Ahnaou A, Huysmans H, Jacobs T, Drinkenburg WH. Cortical EEG oscillations and network connectivity as efficacy indices for assessing drugs with cognition enhancing potential.
Neuropharmacology. 86: 362-77 (2014)
100. Drinkenburg WH, Ruigt GS, Ahnaou A. Pharmaco-EEG Studies in Animals: An Overview of Contemporary Translational Applications. Neuropsychobiology. 72: 151-64 (2015)
101. Buccafusco JJ, Terry AV, Jr., Webster SJ, Martin D, Hohnadel EJ, Bouchard KA, et al. The scopolamine-reversal paradigm in rats and monkeys: the importance of computer-assisted operant-conditioning memory tasks for screening drug candidates. Psychopharmacology (Berl). 199:
481-94 (2008)
102. Andersen MB, Fink-Jensen A, Peacock L, Gerlach J, Bymaster F, Lundbaek JA, et al. The muscarinic M1/M4 receptor agonist xanomeline exhibits antipsychotic-like activity in Cebus apella monkeys. Neuropsychopharmacology. 28: 1168-75 (2003)
103. Itil TM, Itil KZ. The significance of pharmacodynamic measurements in the assessment of bioavailability and bioequivalence of psychotropic drugs using CEEG and dynamic brain mapping. J Clin Psychiatry. 47 Suppl: 20-7 (1986)
104. Itil TM, Mucci A, Eralp E. Dynamic brain mapping methodology and application. Int J Psychophysiol. 10: 281-91 (1991)
105. Itil TM, Itil KZ. Quantitative EEG Brain Mapping In Psychotropic Drug Development, Drug Treatment Selection, and Monitoring. Am J Ther. 2: 359-67 (1995)
106. Thakor NV, Tong S. Advances in quantitative electroencephalogram analysis methods. Annu Rev Biomed Eng. 6: 453-95 (2004)
107. Coburn KL, Lauterbach EC, Boutros NN, Black KJ, Arciniegas DB, Coffey CE. The value of quantitative electroencephalography in clinical psychiatry: a report by the Committee on Research of the American Neuropsychiatric Association. J Neuropsychiatry Clin Neurosci. 18: 460-500 (2006) 108. Leiser SC, Dunlop J, Bowlby MR, Devilbiss DM. Aligning strategies for using EEG as a surrogate
biomarker: a review of preclinical and clinical research. Biochem Pharmacol. 81: 1408-21 (2011)